Abstract | BACKGROUND AND OBJECTIVE: METHODS: RESULTS: There were no significant differences between treatment groups in changes in serum phosphorus (p=0.378) and adjusted serum calcium levels (p=0.980), but there were more hypercalcaemic events in the calcium acetate group (12.0% vs 3.7%) during treatment. Total serum cholesterol (p<0.001) and low-density lipoprotein ( LDL) cholesterol (p<0.001) levels decreased significantly compared with baseline in the sevelamer group. The decreases in total serum cholesterol and LDL cholesterol were correlated with the reductions in serum phosphorus levels during sevelamer treatment (correlation coefficient [r]=0.266 and 0.386, respectively). Serum uric acid decreased significantly in the sevelamer group (p=0.020), and this change was correlated with serum phosphorus changes (r=0.458). Decreases in plasma H2O2-related radicals, the major oxidative stressor in ROS (p<0.001), but not superoxide (p=0.593), were observed after sevelamer treatment. CONCLUSION:
|
Authors | Yu-Feng Lin, Chiang-Ting Chien, Wei-Chih Kan, Yung-Ming Chen, Tzong-Shinn Chu, Kuan-Yu Hung, Tun-Jun Tsai, Kwan-Dun Wu, Ming-Shiou Wu |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 31
Issue 4
Pg. 257-67
( 2011)
ISSN: 1173-2563 [Print] New Zealand |
PMID | 21299254
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Chelating Agents
- Lipids
- Polyamines
- Reactive Oxygen Species
- Uric Acid
- Phosphorus
- Sevelamer
- Calcium
|
Topics |
- Adult
- Aged
- Calcium
(blood)
- Chelating Agents
(therapeutic use)
- Female
- Humans
- Kidney Failure, Chronic
(blood, complications, drug therapy)
- Lipids
(blood)
- Male
- Middle Aged
- Phosphorus
(blood)
- Polyamines
(therapeutic use)
- Reactive Oxygen Species
(metabolism)
- Renal Dialysis
- Sevelamer
- Uric Acid
(blood)
|